The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection
- PMID: 27816493
- PMCID: PMC5472097
- DOI: 10.1016/j.jhep.2016.10.027
The HCV care continuum does not end with cure: A call to arms for the prevention of reinfection
Conflict of interest statement
Dr. Falade-Nwulia has nothing to disclose. Dr. Sulkowski reports research grants and personal fees from AbbVie, personal fees from Cocrystal, research grants and personal fees from Gilead, research grants and personal fees from Janssen, research grants and personal fees from Merck, and personal fees from Trek.
Figures
Comment on
-
HCV reinfection incidence and spontaneous clearance rates in HIV-positive men who have sex with men in Western Europe.J Hepatol. 2017 Feb;66(2):282-287. doi: 10.1016/j.jhep.2016.09.004. Epub 2016 Sep 17. J Hepatol. 2017. PMID: 27650285
References
-
- World Health Organization. Draft global health sector strategy on viral hepatitis 2016–2021. The first of it’s kind. 2015
-
- Martin NK, Thornton A, Hickman M, Sabin C, Nelson M, Cooke GS, et al. Can hepatitis C virus (HCV) direct-acting antiviral treatment as prevention reverse the HCV epidemic among men who have sex with men in the United Kingdom? Epidemiological and modeling insights Clin Infect Dis. 2016;62:1072–1080. - PMC - PubMed
-
- Lambers FA, Prins M, Thomas X, Molenkamp R, Kwa D, Brinkman K, et al. Alarming incidence of hepatitis C virus re-infection after treatment of sexually acquired acute hepatitis C virus infection in HIV-infected MSM. Aids. 2011;25:F21–F27. - PubMed
-
- Martin TC, Martin NK, Hickman M, Vickerman P, Page EE, Everett R, et al. Hepatitis C virus reinfection incidence and treatment outcome among HIV-positive MSM. Aids. 2013;27:2551–2557. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
